Interventional Oncology: Advances in Cancer Care

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 7 November 2025 | Viewed by 146

Special Issue Editor


E-Mail Website
Guest Editor
Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43240, USA
Interests: cancer; interventional radiology

Special Issue Information

Dear Colleagues,

As one of the most rapidly evolving fields in cancer treatment, interventional oncology combines cutting-edge minimally invasive techniques with advanced imaging to precisely target tumors. This Special Issue aims to highlight recent innovations, clinical applications, and future trends in interventional oncology, with a focus on improving patient outcomes.

We invite researchers, clinicians, and specialists to contribute original research, reviews, and case reports that explore novel therapies, breakthroughs in imaging technology, and emerging interventional strategies. Topics of interest include, but are not limited to, the following:

  • Ablative techniques (radiofrequency, microwave, cryoablation, etc.);
  • Bland embolization, radioembolization, and chemoembolization;
  • Image-guided drug delivery;
  • Innovations in tumor-targeting technologies;
  • Combined interventional and systemic treatments;
  • Advances in clinical outcomes and quality-of-life improvements.

Submissions for this Special Issue will undergo a rigorous peer-review process and contribute to advancing our understanding of the potential and limitations of interventional oncology in the fight against cancer.

We look forward to your valuable contributions to this timely and impactful Special Issue.

Dr. Mina S. Makary
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional oncology
  • image guided
  • cancer care
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 2971 KiB  
Review
Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma
by Elliott L. Fite and Mina S. Makary
Cancers 2025, 17(9), 1494; https://doi.org/10.3390/cancers17091494 - 29 Apr 2025
Abstract
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide. Despite the high incidence of HCC, mortality remains high, with an estimated 5-year survival rate of less than 20%. Surgical resection represents a potential curative treatment for HCC; however, less than [...] Read more.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide. Despite the high incidence of HCC, mortality remains high, with an estimated 5-year survival rate of less than 20%. Surgical resection represents a potential curative treatment for HCC; however, less than 20% of patients with HCC are candidates for surgical resection. In patients with unresectable HCC, Yttrium-90 (Y90) transarterial radioembolization (TARE) has emerged as an innovative treatment option. This locoregional therapy delivers high doses of radiation directly to liver tumors via intra-arterial injection, allowing for the targeted destruction of malignant cells while sparing surrounding healthy tissue. In this review, we will explore the latest advances in Y90 TARE for the treatment of HCC, focusing on key developments such as the following: (1) improvements in radiation lobectomy and segmentectomy techniques, (2) the introduction of personalized dosimetry, (3) the integration of combination therapies, (4) the use of imageable microspheres, (5) pressure-enabled Y90 delivery systems, and (6) the application of Y90 surrogates. Full article
(This article belongs to the Special Issue Interventional Oncology: Advances in Cancer Care)
Show Figures

Figure 1

Back to TopTop